Previous Article | Next Article ![]()
Infection and Immunity, August 2008, p. 3439-3450, Vol. 76, No. 8
0019-9567/08/$08.00+0 doi:10.1128/IAI.00245-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Jin Qiu,1,2,
Jianbo Chen,1,2,3,
Bridgett Ryan-Payseur,1,2
Dan Huang,1,2
Yunqi Wang,1,2
Lijun Rong,1
Jody A. Melton-Witt,4
Nancy E. Freitag,1 and
Zheng W. Chen1,2*
Department of Microbiology and Immunology,1 Center for Primate Biomedical Research, University of Illinois College of Medicine, Chicago, Illinois 60612,2 Department of Microbiology, Sun Yat-sen University, Guangzhou, China 510080,3 Department of Molecular and Cell Biology, University of California, Berkeley, California 94720-32024
Received 20 February 2008/ Returned for modification 5 April 2008/ Accepted 22 April 2008
While recombinant Listeria monocytogenes strains can be explored as vaccine candidates, it is important to develop attenuated but highly immunogenic L. monocytogenes vaccine vectors. Here, prfA* mutations selected on the basis of upregulated expression of L. monocytogenes PrfA-dependent genes and proteins were assessed to determine their abilities to augment expression of foreign immunogens in recombinant L. monocytogenes vectors and therefore enhance vaccine-elicited immune responses (a prfA* mutation is a mutation that results in constitutive overexpression of PrfA and PrfA-dependent virulence genes; the asterisk distinguishes the mutation from inactivation or stop mutations). A total of 63 recombinant L. monocytogenes vaccine vectors expressing seven individual viral or bacterial immunogens each in nine different L. monocytogenes strains carrying wild-type prfA or having prfA* mutations were constructed and investigated. Mutations selected on the basis of increased PrfA activation in recombinant L. monocytogenes prfA* vaccine vectors augmented expression of seven individual protein immunogens remarkably. Consistently, prime and boost vaccination studies with mice indicated that the prfA(G155S) mutation in recombinant L. monocytogenes
actA prfA* strains enhanced vaccine-elicited cellular immune responses. Surprisingly, the prfA(G155S) mutation was found to enhance vaccine-elicited humoral immune responses as well. The highly immunogenic recombinant L. monocytogenes
actA prfA* vaccine strains were as attenuated as the recombinant parent L. monocytogenes
actA vaccine vector. Thus, recombinant attenuated L. monocytogenes
actA prfA* vaccine vectors potentially are better antimicrobial and anticancer vaccines.
Published ahead of print on 12 May 2008.
L.Y., J.Q., and J.C. contributed equally to this work.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»